Efficacy of High-Dose, Rapid, Hepatitis A and B Vaccination Schedules in Patients With Cirrhosis

Alan J. Wigg; Rachel Wundke; Rosemary McCormick; Kate R. Muller; Jeyamani Ramachandran; Sumudu K. Narayana; Richard J. Woodman

doi:10.1016/j.cgh.2018.08.047

Efficacy of High-Dose, Rapid, Hepatitis A and B Vaccination Schedules in Patients With Cirrhosis

Alan J. Wigg, Rachel Wundke, Rosemary McCormick, Kate R. Muller, Jeyamani Ramachandran, Sumudu K. Narayana, Richard J. Woodman

Research output: Contribution to journal › Short survey › peer-review

2 Citations (Scopus)

Abstract

Patients with cirrhosis have increased morbidity from hepatitis A virus (HAV) and hepatitis B virus (HBV) infections, and vaccination against these infections is an important standard of care. ^1,2 However, vaccination in patients with cirrhosis is hindered by immune dysfunction and there is limited high-quality literature available. The aim of this work therefore was to compare immune responses of standard dose (SD) with high-dose accelerated (HDA) vaccination in cirrhotic patients.

Original language	English
Pages (from-to)	1210-1212.e1
Number of pages	3
Journal	Clinical Gastroenterology and Hepatology
Volume	17
Issue number	6
DOIs	https://doi.org/10.1016/j.cgh.2018.08.047
Publication status	Published - 1 May 2019

Access to Document

10.1016/j.cgh.2018.08.047Licence: In Copyright

Link to publication in Scopus

Fingerprint Dive into the research topics of 'Efficacy of High-Dose, Rapid, Hepatitis A and B Vaccination Schedules in Patients With Cirrhosis'. Together they form a unique fingerprint.

Cite this

@article{4c54ea83bab046cc84ea40341429047b,

title = "Efficacy of High-Dose, Rapid, Hepatitis A and B Vaccination Schedules in Patients With Cirrhosis",

abstract = " Patients with cirrhosis have increased morbidity from hepatitis A virus (HAV) and hepatitis B virus (HBV) infections, and vaccination against these infections is an important standard of care. 1,2 However, vaccination in patients with cirrhosis is hindered by immune dysfunction and there is limited high-quality literature available. The aim of this work therefore was to compare immune responses of standard dose (SD) with high-dose accelerated (HDA) vaccination in cirrhotic patients. ",

author = "Wigg, {Alan J.} and Rachel Wundke and Rosemary McCormick and Muller, {Kate R.} and Jeyamani Ramachandran and Narayana, {Sumudu K.} and Woodman, {Richard J.}",

year = "2019",

month = may,

day = "1",

doi = "10.1016/j.cgh.2018.08.047",

language = "English",

volume = "17",

pages = "1210--1212.e1",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

number = "6",

}

Efficacy of High-Dose, Rapid, Hepatitis A and B Vaccination Schedules in Patients With Cirrhosis. / Wigg, Alan J.; Wundke, Rachel; McCormick, Rosemary; Muller, Kate R.; Ramachandran, Jeyamani; Narayana, Sumudu K.; Woodman, Richard J.

In: Clinical Gastroenterology and Hepatology, Vol. 17, No. 6, 01.05.2019, p. 1210-1212.e1.

Research output: Contribution to journal › Short survey › peer-review

TY - JOUR

T1 - Efficacy of High-Dose, Rapid, Hepatitis A and B Vaccination Schedules in Patients With Cirrhosis

AU - Wigg, Alan J.

AU - Wundke, Rachel

AU - McCormick, Rosemary

AU - Muller, Kate R.

AU - Ramachandran, Jeyamani

AU - Narayana, Sumudu K.

AU - Woodman, Richard J.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Patients with cirrhosis have increased morbidity from hepatitis A virus (HAV) and hepatitis B virus (HBV) infections, and vaccination against these infections is an important standard of care. 1,2 However, vaccination in patients with cirrhosis is hindered by immune dysfunction and there is limited high-quality literature available. The aim of this work therefore was to compare immune responses of standard dose (SD) with high-dose accelerated (HDA) vaccination in cirrhotic patients.

AB - Patients with cirrhosis have increased morbidity from hepatitis A virus (HAV) and hepatitis B virus (HBV) infections, and vaccination against these infections is an important standard of care. 1,2 However, vaccination in patients with cirrhosis is hindered by immune dysfunction and there is limited high-quality literature available. The aim of this work therefore was to compare immune responses of standard dose (SD) with high-dose accelerated (HDA) vaccination in cirrhotic patients.

UR - http://www.scopus.com/inward/record.url?scp=85063128756&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2018.08.047

DO - 10.1016/j.cgh.2018.08.047

M3 - Short survey

C2 - 30144521

AN - SCOPUS:85063128756

VL - 17

SP - 1210-1212.e1

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 6

ER -